Drug Trial Radar · NCT03006237
IS-001 Injection Phase-1 Safety, Tolerance and Pharmacokinetics
Last checked: Nov 19, 2026Latest source record: Mar 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Dec 2016
Primary completion
Dec 2017
Study completion Dec 2017
Sponsor
- Lead sponsor
- Intuitive SurgicalIndustry
- Sponsor type
- Industry
- First posted
- Dec 30, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase 1 Open Label Single Center Safety, Tolerability and Pharmacokinetic Study of IS-001
Conditions
- Hysterectomy
- Surgery
Interventions
IS-001Drug
10mg, 20mg or 40 mg IV IS-001 drug administered during surgery
da Vinci® Si/Xi Surgical SystemDevice
robot-assisted minimally invasive hysterectomy surgery performed with da Vinci® Si/Xi Surgical System with Firefly® Fluorescent Imaging
Primary outcomes
What the sponsor says the trial is designed to measure.
- Monitor Safety Parameters (vital signs, ECG, serum chemistry and hematology, urinalysis and adverse events)Time frame: 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Las Palmas Medical Center
El Paso, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.